ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "gout"

  • Abstract Number: L05 • ACR Convergence 2024

    Prolonged Plasma Urate-Lowering After a Single Intravenous Administration of PRX-115, a Novel PEGylated Uricase, in Participants with Elevated Urate Levels

    Christian Schwabe1, Orit Cohen Barak2, Alexandra Cole3, Hadar Reuveni2, Liron Shelev2, Liora Blinder-Haddad2 and Nicola Dalbeth4, 1NZCR, Auckland, New Zealand, 2Protalix Ltd, Karmiel, Israel, 3NZCR, Christchurch, New Zealand, 4University of Auckland, Auckland, New Zealand

    Background/Purpose: PEGylated uricases have already demonstrated therapeutic modality in the treatment of refractory gout patients. PRX-115 is a recombinant homotetrameric uricase enzyme, produced from Candida…
  • Abstract Number: 0267 • ACR Convergence 2024

    IL-17 Participates in the Pathogenesis of Chronic Gouty Arthritis

    Hong Di1, Xinxin Han1, Yun Zhang2 and Xuejun Zeng1, 1Peking Union Medical College Hospital, Beijing, China, 2Peking Union Medical College Hospital (CAMS), Beijing, China

    Background/Purpose: Chronic gouty arthritis (CGA) is different from acute gouty arthritis  (AGA), its main characteristics include repeated or even persistent joint symptoms, tophus and bone destruction.…
  • Abstract Number: 0907 • ACR Convergence 2024

    Association of Rare and Common Genetic Variants in MOCOS with Inadequate Response to Allopurinol

    Niamh Fanning1, Murray Cadzow2, Ruth Topless3, Chris Frampton4, Nicola Dalbeth5, Tony Merriman6 and Lisa Stamp4, 1University of Otago, Christchurch, New Zealand, 2University of Otago, Dunedin 9054, New Zealand, 3University of Otago, Dunedin, New Zealand, 4University of Otago, Christchurch, Christchurch, New Zealand, 5University of Auckland, Auckland, New Zealand, 6University of Alabama at Birmingham, Homewood, AL

    Background/Purpose: The minor allele of the common rs2231142 (Q141K) ABCG2 variant predicts inadequate response to allopurinol urate lowering therapy (ULT). We hypothesize that additional variants in genes…
  • Abstract Number: 1093 • ACR Convergence 2024

    Risk of Dementia in Patients with Gout: Potential Impact of Survival Bias

    Joshua Baker1, Lindsay Helget2, chung-Chou Chang3, Bryant England2, Brian Coburn1, Harlan Sayles2, Punyasha Roul4 and Ted Mikuls2, 1University of Pennsylvania, Philadelphia, PA, 2University of Nebraska Medical Center, Omaha, NE, 3University of Pittsburgh, Pittsburgh, PA, 4UNMC, Omaha, NE

    Background/Purpose: Prior studies reported a lower risk of dementia among patients with gout suggesting that hyperuricemia might play a neuroprotective role. However, risk estimates for…
  • Abstract Number: 1885 • ACR Convergence 2024

    Effect of Physical Activity on Mortality in Rheumatoid Arthritis: A Dose-Response Analysis

    Bo Chen1 and Qibing Xie2, 1Chenbo, Chendu, Sichuan, China, 2Department of Rheumatology and Immunology, Chengdu, Sichuan, China

    Background/Purpose: Patients with Rheumatoid arthritis (RA) tend to perform less physical activity compared to the recommended guidelines. The long-term effects of physical activity on mortality…
  • Abstract Number: 2018 • ACR Convergence 2024

    Non-adherence to Urate Lowering Therapy in Gout After 5 Years Is Related to Poor Outcomes – Results from the NOR-Gout Study

    Tillmann Uhlig1, Lars F Karoliussen1, Joseph Sexton2, Sella A. Provan2, Espen A. Haavardsholm3, Nicola Dalbeth4 and Hilde B Hammer1, 1Diakonhjemmet Hospital, Oslo, Norway, 2Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 3Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 4University of Auckland, Auckland, New Zealand

    Background/Purpose: People with gout need to adhere to medication over time to achieve good outcomes. We assessed self-reported adherence to medication with urate lowering therapy…
  • Abstract Number: 0268 • ACR Convergence 2024

    Weight Loss Induced by Anti-obesity Medications and Gout Among Overweight and Obesity Individuals: A Population-based Cohort Study

    Jie Wei1, Yilun Wang2, Nicola Dalbeth3, Junqing Xie4, Jing Wu5, Chao Zeng6, Guanghua Lei7 and Yuqing Zhang8, 1Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China (People's Republic), 2Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China (People's Republic), 3University of Auckland, Auckland, New Zealand, 4Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 5Hunan Key Laboratory of Joint Degeneration and Injury, Changsha, China (People's Republic), 6Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University; Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China (People's Republic), 7Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China (People's Republic), 8Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School; The Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Weight loss is conditionally recommended for gout management; however, the magnitude of the effect of weight loss on incident gout and recurrent gout flares…
  • Abstract Number: 0920 • ACR Convergence 2024

    TGF-β Activated Kinase 1 Inhibition by Pentagalloyl Glucose Inhibits NLRP3 Inflammasome Formation and Ameliorates MSU-Induced Inflammation

    Paul Panipinto1 and Salahuddin Ahmed2, 1Washington State University College of Pharmaceutical Science and Molecular Medicine, Spokane, WA, 2Washington State University, Spokane, WA

    Background/Purpose: Monosodium urate (MSU)-induced inflammation is caused by the deposition of MSU crystals in the joints and periarticular tissues under conditions of hyperuricemia. These deposits…
  • Abstract Number: 1095 • ACR Convergence 2024

    The Incidence of Gout Among Individuals with Hyperuricemia over Time – an Insight from a Nationwide Cohort Study

    Shay Brikman1, Amir Bieber2, Liel Serfaty, MA3, Ran Abuhasira, MD, PhD4, Nadav Rappoport5 and Naomi Schlesinger6, 1Emek Medical Center, Afula, Israel, 2Emek Medical Center, Clalit Health Services, Raanana, Israel, 3Department of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Be'er Sheva, Israel, 4Clinical Research Center, Soroka University Medical Center, Be'er Sheva, Israel, 5Ben-Gurion University of the Negev, Beer-Sheva, Israel, 6University of Utah, Salt Lake City, UT

    Background/Purpose: Hyperuricemia is considered the most important risk factor for developing Gout, the most common adult inflammatory arthritis. Hyperuricemia is defined by a serum urate…
  • Abstract Number: 1921 • ACR Convergence 2024

    Devastating Morbidity and Mortality Rates in the Hmong Population with a Diagnosis of Gout Who Had a COVID-19 Infection

    Kari Falaas1, Michael Schnaus2, Margaret Singer3, Allison Hochstetler3, Pang Nhia Khang4, Katherine Schmiechen4 and Elie Gertner3, 1University of Minnesota, Regions Hospital, Minneapolis, MN, 2University of Minnesota, Regions Hospital, Methodist Hospital, Minneapolis, 3University of Minnesota, Regions Hospital, Minneapolis, 4Regions Hospital, Minneapolis

    Background/Purpose: Hyperuricemia is associated with an elevated risk of developing cardiovascular diseases, diabetes, chronic kidney disease, and metabolic syndromes. The Hmong population, in particular, has…
  • Abstract Number: 2019 • ACR Convergence 2024

    Safety and Efficacy of SEL-212 in the US and ex-US Subgroups: Results from the Phase 3 DISSOLVE Studies

    Michael Pillinger1, Alan Kivitz2, Atul Singhal3, Anand Patel4, Rehan Azeem5, Aletta Falk6, Bhavisha Desai7, Hugues Santin-Janin8 and Herbert Baraf9, 1New York University Grossman School of Medicine, New York,, NY, 2Altoona Center for Clinical Research, Duncansville, PA, 3Southwest Arthritis Research Group, Mesquite, TX, 4Conquest Research, Winter Park, FL, 5Sobi Inc., Waltham, MA, 6Sobi, Stockholm, Sweden, 7Sobi, Glastonbury, CT, 8Sobi, BETTENDORF (68560), France, 9Center for Rheumatology and Bone Research, Wheaton, MD

    Background/Purpose: The DISSOLVE Phase 3 study program investigated the efficacy and safety of SEL-212, a novel, once-monthly, two-component infusion therapy consisting of pegadricase (SEL-037, a…
  • Abstract Number: 0271 • ACR Convergence 2024

    Intercritical Gout Represents a Systemic Inflammatory State

    Tanner Ourada1, Austin Wheeler2, Michael Duryee2, Bryant England2, Richard Reynolds3, James O'Dell2, Jeff Newcomb2, Michael Pillinger4, Robert Terkeltaub5, Ryan Ferguson6, Mary Brophy6, Tony Merriman7 and Ted Mikuls2, 1University of Nebraska-Medical Center: College of Medicine, Omaha, NE, 2University of Nebraska Medical Center, Omaha, NE, 3University of Alabama at Birmingham, Birmingham, AL, 4New York University Grossman School of Medicine, New York,, NY, 5Retired, San Diego, CA, 6Veterans Affairs, Boston, MA, 7University of Alabama at Birmingham, Homewood, AL

    Background/Purpose: The presence of systemic inflammation during gout flares is well characterized. While initial research suggests inflammation persists in intercritical gout, these reports have come…
  • Abstract Number: 0934 • ACR Convergence 2024

    Screening NLRP3 Drug Candidates in Clinical Development:Lessons from Existing and Emerging Technologies

    Isak Tengesdal1, Carlo Marchetti1, Tim L.Th. Jansen2, Marc Y. Donath3, Naomi Schlesinger4 and Charles Dinarello1, 1University of Colorado, Denver, CO, 21VieCuri Medisch Centrum, Venlo, Netherlands, 3University of Basel, Basel, Switzerland, 4University of Utah, Salt Lake City, UT

    Background/Purpose: NLRP3 is emerging as an attractive upstream target of the pathway to down-modulate rather than to completely neutralize IL-1ß levels in both acute and…
  • Abstract Number: 1096 • ACR Convergence 2024

    Exploring Multi Factorial Model for the Prediction of Gout in Patients with Hyperuricemia

    Shay Brikman1, Liel Serfaty, MA2, Ran Abuhasira, MD, PhD3, Naomi Schlesinger4, Nadav Rappoport5 and Amir Bieber6, 1Emek Medical Center, Afula, Israel, 2Department of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Be'er Sheva, Israel, 3Clinical Research Center, Soroka University Medical Center, Be'er Sheva, Israel, 4University of Utah, Salt Lake City, UT, 5Ben-Gurion University of the Negev, Beer-Sheva, Israel, 6Emek Medical Center, Clalit Health Services, Raanana, Israel

    Background/Purpose: Hyperuricemia (HU) is considered the most important factor preceding Gout. Yet, only a portion of hyperuricemic people develop Gout. Using a machine learning modeling…
  • Abstract Number: 1992 • ACR Convergence 2024

    Gout FlaresFollowingImmune Checkpoint Inhibitors Treatment

    Austen herron1, Miao Ting Lai2, Naomi Schlesinger3, Sauer brian4, Jorge Rojas5, shardool Patel3, Madeline O’Sullivan3, grant Cannon6 and Tawnie Braaten3, 1Salt Lake City VA and University of Utah, Salt Lake City, UT, 2University of Utah and Salt Lake City VA, salt lake city, 3University of Utah, Salt Lake City, UT, 4Salt Lake City VA/University of Utah, Salt Lake City, UT, 5Seattle VA, Mexico, Mexico, 6University of Utah and Salt Lake City VA, Salt Lake City, UT

    Background/Purpose: Immune checkpoint inhibitors (ICIs) produce immune-related adverse events in patients with rheumatic diseases that can often present as a flare of the underlying condition.…
  • 1
  • 2
  • 3
  • …
  • 45
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology